Select Page

Janssen Pharmaceuticals, Inc. announced on September 21, 2016 that the U.S. Food and Drug Administration (FDA) approved Invokamet® XR, it’s latest medication for Type 2 Diabetes. Invokamet® XR is an addition to a new class of medications for Type 2 diabetes treatments, known as a sodium-glucose co-transporter 2 (SGLT2) inhibitors. Along with Invokana® (canaglifozin), which has been a source of recent litigation against J&J, these medications help by stopping glucose from being reabsorbed into the blood in the kidneys.

However, although this new class of medications can help people who suffer from Type 2 diabetes, the side effects associated with these types of drugs are still a cause for concern. Invokana® is the most popular treatment for Type 2 diabetes after being approved in 2013, yet lawsuit numbers against its manufacturer, Johnson & Johnson, continue to increase.

In 2015, studies revealed that Invokana® could be linked to some serious potential side effects, including kidney disease, heart attacks and ketoacidosis. Families are filing lawsuits across the country against J&J, alleging the company failed to warn patients and physicians of the increased risks of complications linked to this medication.

If you’ve been affected by this drug, you can learn more about it here.